Detalles de la búsqueda
1.
Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial.
Catheter Cardiovasc Interv
; 93(7): 1374-1381, 2019 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31116908
2.
Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
Am Heart J
; 194: 73-82, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29223437
3.
Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Catheter Cardiovasc Interv
; 90(6): 1027-1037, 2017 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28493641
4.
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Catheter Cardiovasc Interv
; 90(6): 1016-1026, 2017 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28498562
5.
Bivalirudin started during emergency transport for primary PCI.
N Engl J Med
; 369(23): 2207-17, 2013 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24171490
6.
Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.
Catheter Cardiovasc Interv
; 88(2): 174-81, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26332193
7.
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial.
Eur Heart J
; 35(36): 2460-7, 2014 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-24849104
8.
Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy.
J Thromb Thrombolysis
; 31(2): 139-45, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20872045
9.
Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial.
Eur Heart J Acute Cardiovasc Care
; 7(6): 514-521, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28631502
10.
ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy.
Eur Heart J Acute Cardiovasc Care
; 6(5): 404-411, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26250825
11.
Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials.
Eur Heart J Acute Cardiovasc Care
; 6(7): 659-665, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27287251
12.
One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.
JAMA Cardiol
; 2(7): 791-796, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28273285
13.
Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial.
Open Heart
; 4(2): e000677, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29225903
14.
Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials.
Circ Cardiovasc Interv
; 9(5): e003272, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27165710
15.
Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial.
Int J Cardiol
; 211: 119-23, 2016 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26995053
16.
Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study.
J Am Coll Cardiol
; 68(6): 589-599, 2016 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27208464
17.
Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials.
Am J Cardiol
; 118(1): 6-16, 2016 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27181566
18.
Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial.
Circ Cardiovasc Interv
; 8(6): e002049, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26056249
19.
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
J Am Coll Cardiol
; 65(1): 27-38, 2015 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-25572507
20.
Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).
JACC Cardiovasc Interv
; 8(1 Pt B): 214-220, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25616927